Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becatecarin vs 5-FU/LV in Advanced Biliary Tumors
NCT00090025Phase 3Terminated
- Sponsor
- Helsinn
- Start
- Sep 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of becatecarin in biliary tract cancer (BTC) (2 arms), sponsored by Helsinn. Primary endpoint: Overall Survival. Started Sep 2004; status: terminated.
02
Drugs
becatecarin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00090025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090025.